Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination chemotherapy regimen consisting of three drugs: - **Ifosfamide** is an alkylating agent that exerts its anti-cancer effect by causing DNA cross-linking and damage, leading to cell death. It is used in the treatment of various cancers, including lung cancer, sarcomas, and lymphomas[3][4]. - **Verapamil** is a calcium channel blocker primarily used for cardiovascular conditions but also acts as a chemosensitizer. In oncology regimens, it inhibits P-glycoprotein (P-gp), thereby reversing multidrug resistance in tumor cells and enhancing the efficacy of chemotherapeutic agents like vindesine[1][8]. - **Vindesine** is a vinca alkaloid that inhibits microtubule formation by binding to tubulin beta-1 chain, arresting cells in metaphase during mitosis. It is mainly indicated for acute lymphocytic leukemia and non-small cell lung cancer[5]. The combination has been studied particularly in advanced non-small cell lung cancer (NSCLC), where verapamil was added to sensitize tumors resistant to chemotherapy by inhibiting drug efflux mechanisms[1]. The regimen aims to maximize cytotoxicity against tumor cells while overcoming resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ifosfamide + verapamil + vindesine.